TY - JOUR
T1 - Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs
AU - Lee, Soo Han
AU - Kang, Hyun Ji
AU - Jin, Seok Joon
AU - Park, Do Yang
AU - Choi, Yoon Ji
AU - Choi, Byung Moon
AU - Lee, Eun Kyung
AU - Noh, Gyu Jeong
N1 - Funding Information:
We are grateful to Ae-Kyung Hwang, B.S. (technician), Hyun-Jeong Park, B.S. (technician), and A-rum Kim, B.S. (technician) from the Clinical Research Center of Asan Medical Center (Seoul, Korea) for measuring plasma concentrations of propofol. This work was supported by the Student Research Grant (12-13) of University of Ulsan College of Medicine and Grant No. 2010-301 from the Asan Institute for Life Sciences, Seoul, Korea.
Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2014/11/9
Y1 - 2014/11/9
N2 - This study aimed to characterize pharmacodynamic interaction between propofol and aminophylline. Nine beagle dogs were randomly allocated at the propofol rates of 0.75 (group A), 1.00 (group B), and 1.25 (group C) mg/kg/min. During period 1, propofol only was infused, while during period 2, aminophylline only, at the rate of 0.69 (group A), 1.37 (group B), and 2.62 (group C) mg/kg/h. During periods 3–5, the two drugs were co-administered. The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h. The aminophylline was infused from 0 to 30 h, and the propofol was infused at 24 h for 20 min. Blood samples and electroencephalograms were obtained at preset intervals. In the linear regression between log-transformed doses of aminophylline and AUCinf, the slope was 0.6976 (95 % CI 0.5242–0.8710). Pharmacokinetics of aminophylline was best described by a one-compartment, with enzyme auto-induction, model. Pharmacokinetics and pharmacodynamics of propofol were best described by a three-compartment model and a sigmoid Emax model, respectively. Pharmacodynamic parameter estimates of propofol were: ke0 = 0.805/min, E0 = 0.76, Emax = 0.398, Ce50 na = 2.38 μg/mL (without aminophylline-exposure), Ce50 wa = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21. Propofol becomes less potent when exposed to aminophylline. Pharmacodynamic antagonistic interaction of aminophylline with propofol sedation, may occur, not in a dose-dependent manner, but in an all-or-none response.
AB - This study aimed to characterize pharmacodynamic interaction between propofol and aminophylline. Nine beagle dogs were randomly allocated at the propofol rates of 0.75 (group A), 1.00 (group B), and 1.25 (group C) mg/kg/min. During period 1, propofol only was infused, while during period 2, aminophylline only, at the rate of 0.69 (group A), 1.37 (group B), and 2.62 (group C) mg/kg/h. During periods 3–5, the two drugs were co-administered. The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h. The aminophylline was infused from 0 to 30 h, and the propofol was infused at 24 h for 20 min. Blood samples and electroencephalograms were obtained at preset intervals. In the linear regression between log-transformed doses of aminophylline and AUCinf, the slope was 0.6976 (95 % CI 0.5242–0.8710). Pharmacokinetics of aminophylline was best described by a one-compartment, with enzyme auto-induction, model. Pharmacokinetics and pharmacodynamics of propofol were best described by a three-compartment model and a sigmoid Emax model, respectively. Pharmacodynamic parameter estimates of propofol were: ke0 = 0.805/min, E0 = 0.76, Emax = 0.398, Ce50 na = 2.38 μg/mL (without aminophylline-exposure), Ce50 wa = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21. Propofol becomes less potent when exposed to aminophylline. Pharmacodynamic antagonistic interaction of aminophylline with propofol sedation, may occur, not in a dose-dependent manner, but in an all-or-none response.
KW - Aminophylline
KW - Interaction
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Propofol
UR - http://www.scopus.com/inward/record.url?scp=84911964761&partnerID=8YFLogxK
U2 - 10.1007/s10928-014-9377-x
DO - 10.1007/s10928-014-9377-x
M3 - Article
C2 - 25150710
AN - SCOPUS:84911964761
SN - 1567-567X
VL - 41
SP - 599
EP - 612
JO - Journal of Pharmacokinetics and Pharmacodynamics
JF - Journal of Pharmacokinetics and Pharmacodynamics
IS - 6
ER -